Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DYZY01
- Development stage
- Preclinical
- Lead developer
- Deyi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DYZY01 is a new drug whose main ingredient is high-purity cannabidiol, a non-psychoactive constituent of cannabinoids. It alleviates pulmonary hypertension by inhibiting endothelial cell pyroptosis and rescuing endothelial dysfunction. The mechanism involves reducing mean pulmonary arterial pressure (mPAP), right ventricular hypertrophy index (RVHI), and reversing pulmonary vascular remodeling. This is achieved by inhibiting the NF-κB/NLRP3/Caspase-1 pathway and improving endothelial vascular function[1][3].
02
Targets
CASP1 (Caspase-1)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)NF-κB
Beyond the preview
Go deeper on DYZY01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DYZY01.